Palliative chemotherapy with or without cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck: Indian tertiary care retrospective analysis | Zendy

Bahl Ankur | Zendy; Bhatia Komal | Zendy; Choudhary Pragati | Zendy; Singhla Suhas | Zendy; Shrivastava Gunjan | Zendy; Bal Jaspriya | Zendy; Anand Anil K. | Zendy; Chaturvedi Harit | Zendy; Dua Bharat | Zendy

Premium

Palliative chemotherapy with or without cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck: Indian tertiary care retrospective analysis

Author(s) -

Bahl Ankur,

Bhatia Komal,

Choudhary Pragati,

Singhla Suhas,

Shrivastava Gunjan,

Bal Jaspriya,

Anand Anil K.,

Chaturvedi Harit,

Dua Bharat

Publication year - 2020

Publication title -

head and neck

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.012

H-Index - 127

eISSN - 1097-0347

pISSN - 1043-3074

DOI - 10.1002/hed.26070

Subject(s) - cetuximab , medicine , chemotherapy , oncology , head and neck squamous cell carcinoma , head and neck cancer , head and neck , radiation therapy , surgery , cancer , colorectal cancer

Background We report our experience with Indian patients who received palliative chemotherapy with/without cetuximab for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Methods Data from 229 R/M SCCHN patients treated with cetuximab and chemotherapy (n = 140) or chemotherapy alone (n = 89) were retrospectively analyzed for response rate (RR), progression‐free survival (PFS), overall survival (OS), and safety. Results Patients receiving cetuximab with chemotherapy demonstrated significant increase in RR (77.1% vs 44.9%, P = .0001), PFS (8.1 vs 6.1 months, P = .039), and OS (11.8 vs 8.0 months, P = .002) compared with patients receiving chemotherapy alone. Continuing cetuximab and changing chemotherapy combination (second line and beyond) in fit patients doubled OS (13.5 vs 6.1 months, P = .001). Adverse effects, except skin reactions (more in the cetuximab with chemotherapy group; P = .001), were similar in both groups. Conclusion Adding cetuximab to chemotherapy improved ORR, PFS, and OS in Indian R/M SCCHN patients, and cetuximab was well tolerated.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research